New York, NY (Press Release) – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on translating today’s medical breakthroughs in cell and gene ther­a­pies into poten­tial cures for hema­to­logic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treat­ment center, has begun enrolling patients with re­lapsed or treat­ment-resistant multiple myeloma in an inno­va­tive CS1 chi­meric an­ti­gen re­cep­tor (CAR) T cell ther­apy (MB-104) trial.

The Phase 1 clin­i­cal trial is the first au­tol­o­gous CAR T trial to target the CS1 protein, …